In a report released on January 23, Julien Richer from Kepler Capital maintained a Buy rating on DO & CO Aktiengesellschaft (0E64 – Research Report), with a price target of €210.00.

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2024: Cash: € 349,630.55 Number of shares ...

24/01 FW Kepler Cheuvreux relève le prix cible pour Investor à 357 SEK (346) et réaffirme son intention de l'acheter. 24/01 FW DNB relève l'objectif de prix pour Investor à 345 SEK (330 ...

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...

On Wednesday, Kepler Cheuvreux initiated coverage on Nexity (EPA:NEXI) SA (NXI:FP), a prominent player in the French real estate market, assigning a Hold rating to the company's shares. The research ...

On Wednesday, Kepler Cheuvreux began covering Kaufman & Broad S.A. (KOF:FP) (OTC: KFMNF) with a Buy rating and set a price target of €39.10. The firm's analysts pointed to the structural trends ...

On Wednesday, Kepler Cheuvreux initiated coverage on Nexity (EPA:NEXI) SA (NXI:FP), a prominent player in the French real estate market, assigning a Hold rating to the company's shares.

despite the rich getting conspicuously richer and the poor getting demonstrably poorer, continue to push the myth of drip-down economics. While the little people fight amongst themselves about the ...